Heliogen, Inc. Announces Full Year 2021 Financial and Operational Results
Full-Year 2021 Highlights
-
Finalized
$39 million U.S. Department of Energy award for deployment of AI-enabled concentrated solar technology - Completed first field test of autonomous robots designed to reduce installation and maintenance costs
- Announced start of equipment procurement for first commercial-scale facility collaboration with Woodside Energy to deploy Heliogen’s power technology
- Held successful demonstration of green hydrogen production using the Company’s core concentrated solar technology in partnership with Bloom Energy
-
Closed business combination with
Athena Technology Acquisition Corp. (“Athena”); began trading on the NYSE onDecember 31, 2021
Recent Highlights
-
Began site preparation and setup for first full-scale manufacturing facility in
Long Beach, California -
Awarded exclusive lease rights to
Brenda Solar Energy Zone by theU.S. Bureau of Land Management for the purposes of green hydrogen production
Executive Commentary
“Our mission is bold but simple,” said
Heliogen Progress in 2021 Continues into 2022
During 2021,
“The past year has been transformational in many ways for Heliogen,” said
“As you can tell, the team at
Full-Year 2021 Financial and Operational Results
For the full year 2021,
As of
2022 Guidance
For full-year 2022,
Conference Call Information
The
An archive of the webcast will also be available shortly after the call on the Investor Relations section of Heliogen’s website and will remain available for twelve months.
About
Use of Non-GAAP Financial Information
Management uses certain financial measures, including EBITDA and Adjusted EBITDA, to evaluate our financial and operating performance that are calculated and presented on the basis of methodologies other than in accordance with GAAP. We believe these non-GAAP financial measures are useful to investors and analysts to assess our ongoing financial performance because, when reconciled to their most comparable GAAP financial measures, they provide improved comparability between periods through the exclusion of certain items that we believe are not indicative of our core operating performance, enhances the overall understanding of past financial performance and future prospects, and that may obscure our underlying business results and trends. These measures should not be considered a substitute for, or superior to, measures of financial performance prepared in accordance with GAAP, and our calculations thereof may not be comparable to similarly titled measures reported by other companies. Please see the accompanying tables for reconciliations of the following non-GAAP financial measures for Heliogen’s current and historical results: EBITDA and Adjusted EBITDA.
Forward-Looking Statements
This press release contains certain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Statements that are not historical in nature, including the words “anticipate,” “expect,” “suggests,” “plan,” “believe,” “intend,” “estimates,” “targets,” “projects,” “should,” “could,” “would,” “may,” “will,” “forecast” and other similar expressions are intended to identify forward-looking statements. These forward-looking statements include, but are not limited to, statements regarding our guidance for full-year 2022, the development of our manufacturing and green hydrogen production facilities and future growth opportunities. Forward-looking statements are predictions, projections and other statements about future events that are based on current expectations and assumptions and, as a result, are subject to risks and uncertainties. Many factors could cause actual future events to differ materially from the forward-looking statements in this press release, including but not limited to: (i) our financial and business performance, including risk of uncertainty in our financial projections and business metrics and any underlying assumptions thereunder; (ii) our ability to execute our business model, including market acceptance of our planned products and services and achieving sufficient production volumes at acceptable quality levels and prices; (iii) our ability to access sources of capital to finance operations, growth and future capital requirements; (iv) our ability to maintain and enhance our products and brand, and to attract and retain customers; (v) our ability to scale in a cost-effective manner; (vi) changes in applicable laws or regulations; (vii) the ongoing impacts of the COVID-19 pandemic and the potential impacts of Russia’s invasion of
|
|||||||
($ in thousands, except share data) |
|||||||
Condensed Consolidated Balance Sheets |
|||||||
(unaudited) |
|||||||
|
|
||||||
|
2021 |
|
2020 |
||||
ASSETS |
|
|
|
||||
Cash and cash equivalents |
$ |
190,081 |
|
$ |
18,334 |
|
|
Investments, available-for-sale |
|
32,332 |
|
|
— |
|
|
Other current assets |
|
4,770 |
|
|
241 |
|
|
Total current assets |
|
227,183 |
|
|
18,575 |
|
|
Non-current assets |
|
30,265 |
|
|
1,187 |
|
|
Total assets |
$ |
257,448 |
|
$ |
19,762 |
|
|
LIABILITIES, CONVERTIBLE PREFERRED STOCK AND SHAREHOLDERS’ EQUITY (DEFICIT) |
|
|
|
||||
Trade payables |
$ |
4,645 |
|
$ |
307 |
|
|
Contract liabilities |
|
513 |
|
|
— |
|
|
Contract loss provisions |
|
5,180 |
|
|
— |
|
|
Other current liabilities |
|
6,974 |
|
|
849 |
|
|
Total current liabilities |
|
17,312 |
|
|
1,156 |
|
|
Long-term liabilities |
|
30,861 |
|
|
536 |
|
|
Total liabilities |
|
48,173 |
|
|
1,692 |
|
|
Convertible preferred stock |
|
— |
|
|
45,932 |
|
|
Shareholders’ equity (deficit) |
|
209,275 |
|
|
(27,862 |
) |
|
Total liabilities, convertible preferred stock, and shareholders’ equity (deficit) |
$ |
257,448 |
|
$ |
19,762 |
|
|
||||||||
Condensed Consolidated Statements of Operations and Comprehensive Loss |
||||||||
($ in thousands, except per share and share data) |
||||||||
(unaudited) |
||||||||
|
Years ended |
|||||||
|
2021 |
|
2020 |
|||||
Revenue |
$ |
8,804 |
|
|
$ |
200 |
|
|
Cost of revenue |
|
13,688 |
|
|
|
417 |
|
|
Gross loss |
|
(4,884 |
) |
|
|
(217 |
) |
|
|
|
|
|
|||||
Operating expenses: |
|
|
|
|||||
Selling, general, and administrative |
|
30,386 |
|
|
|
3,713 |
|
|
Research and development |
|
13,478 |
|
|
|
3,583 |
|
|
Total operating expenses |
|
43,864 |
|
|
|
7,296 |
|
|
Operating loss |
|
(48,748 |
) |
|
|
(7,513 |
) |
|
|
|
|
|
|||||
Interest income (expense) |
|
634 |
|
|
|
(3 |
) |
|
SAFE instruments remeasurement |
|
(86,907 |
) |
|
|
— |
|
|
Warrant remeasurement |
|
(6,651 |
) |
|
|
(7 |
) |
|
Other (expense) income, net |
|
(517 |
) |
|
|
86 |
|
|
Net loss before taxes |
|
(142,189 |
) |
|
|
(7,437 |
) |
|
Provision for income taxes |
|
(2 |
) |
|
|
— |
|
|
Net loss |
|
(142,191 |
) |
|
|
(7,437 |
) |
|
Other comprehensive income (loss), net of taxes |
|
|
|
|||||
Unrealized losses on available-for-sale securities |
|
(17 |
) |
|
|
— |
|
|
Cumulative translation adjustment |
|
13 |
|
|
|
— |
|
|
Total comprehensive loss |
$ |
(142,195 |
) |
|
$ |
(7,437 |
) |
|
|
|
|
|
|||||
Loss per share – Basic and Diluted |
$ |
(11.88 |
) |
|
$ |
(0.93 |
) |
|
|
|
|
|
|||||
Weighted average number of shares outstanding – Diluted |
|
11,970,550 |
|
|
|
7,978,512 |
|
Non-GAAP Financial Measures
EBITDA represents consolidated net loss before (i) interest (income) expense, net, (ii) income tax expense (benefit) and (iii) depreciation and amortization expense.
Adjusted EBITDA represents EBITDA adjusted for certain significant non-cash items and items that management believes are not attributable to or indicative of our on-going operations or that may obscure our underlying results and trends.
The following reconciles net loss to EBITDA and Adjusted EBITDA for the periods as shown:
|
Years ended |
|||||||
$ in thousands |
2021 |
|
2020 |
|||||
Net loss |
$ |
(142,191 |
) |
|
$ |
(7,437 |
) |
|
Adjustments |
|
|
|
|||||
Interest (income) expense, net |
|
(634 |
) |
|
|
3 |
|
|
Provision for income taxes |
|
2 |
|
|
|
— |
|
|
Depreciation and amortization |
|
562 |
|
|
|
139 |
|
|
EBITDA |
$ |
(142,261 |
) |
|
$ |
(7,295 |
) |
|
Adjustments |
|
|
|
|||||
SAFE instruments remeasurement |
|
86,907 |
|
|
|
— |
|
|
Warrant remeasurement |
|
6,651 |
|
|
|
7 |
|
|
Share-based compensation |
|
11,380 |
|
|
|
278 |
|
|
Provision for contract losses, net |
|
5,180 |
|
|
|
— |
|
|
Adjusted EBITDA |
$ |
(32,143 |
) |
|
$ |
(7,010 |
) |
View source version on businesswire.com: https://www.businesswire.com/news/home/20220328005922/en/
Heliogen Media Contact:
HeliogenPR@icrinc.com
Heliogen Investor Contact
HeliogenIR@icrinc.com
Source: